{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:57:49Z","timestamp":1777906669696,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T00:00:00Z","timestamp":1484179200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s00415-017-8391-5","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T08:39:48Z","timestamp":1484210388000},"page":"1617-1621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Phenytoin: 80\u00a0years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action"],"prefix":"10.1007","volume":"264","author":[{"given":"Jan M.","family":"Keppel Hesselink","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Kopsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,12]]},"reference":[{"key":"8391_CR1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mi.9.5.1","volume":"9","author":"RJ Anderson","year":"2009","unstructured":"Anderson RJ, Development TLCTCHPCDDa (2009) The little compound that could: how phenytoin changed drug discovery and development. Mol Interv 9:208\u2013214","journal-title":"Mol Interv"},{"issue":"2213","key":"8391_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.85.2213.525","volume":"85","author":"TJ Putnam","year":"1937","unstructured":"Putnam TJ, Merritt HH (1937) Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 85(2213):525\u2013526. doi: 10.1126\/science.85.2213.525","journal-title":"Science"},{"issue":"3","key":"8391_CR3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1528-1157.1986.tb05743.x","volume":"27","author":"WJ Friedlander","year":"1986","unstructured":"Friedlander WJ (1986) Putnam, Merritt, and the discovery of Dilantin. Epilepsia 27(3):S1\u201320","journal-title":"Epilepsia"},{"key":"8391_CR4","doi-asserted-by":"publisher","unstructured":"Yang M, Kozminski DJ, Wold LA, Modak R, Calhoun JD, Isom LL, Brackenbury WJ (2012) Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. Breast Cancer Res Treat 134(2):603\u2013615. doi: 10.1007\/s10549-012-2102-9","DOI":"10.1007\/s10549-012-2102-9"},{"issue":"3","key":"8391_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","volume":"15","author":"R Raftopoulos","year":"2016","unstructured":"Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, Sarrigiannis PG, Hoggard N, Koltzenburg M, Gandini Wheeler-Kingshott CA, Schmierer K, Giovannoni G, Miller DH, Kapoor R (2016) Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 15(3):259\u2013269. doi: 10.1016\/S1474-4422(16)00004-1","journal-title":"Lancet Neurol"},{"key":"8391_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-016-0431-9","author":"Y Wang","year":"2016","unstructured":"Wang Y, Ying X, Chen L, Liu Y, Liang J, Xu C, Guo Y, Wang S, Hu W, Du Y, Chen Z (2016) Electroresponsive nanoparticles improve antiseizure effect of phenytoin in generalized tonic-clonic seizures. Neurotherapeutics. doi: 10.1007\/s13311-016-0431-9","journal-title":"Neurotherapeutics"},{"key":"8391_CR7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1528-1167.2009.02041.x","volume":"3","author":"SD Shorvon","year":"2009","unstructured":"Shorvon SD (2009) Drug treatment of epilepsy in the century of the ILAE: the first 50\u00a0years, 1909\u20131958. Epilepsia 3:69\u201392","journal-title":"Epilepsia"},{"key":"8391_CR8","first-page":"1907","volume":"59","author":"A Hauptmann","year":"1912","unstructured":"Hauptmann A (1912) Luminal bei Epilepsie. M\u00fcnch Med Wochenschr 59:1907\u20131909","journal-title":"M\u00fcnch Med Wochenschr"},{"issue":"1\u20132","key":"8391_CR9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000106217","volume":"3","author":"E Spiegel","year":"1940","unstructured":"Spiegel E, Wycis H (1940) Convulsive reactivity in hypercholesteremia. Confin Neurol 3(1\u20132):262\u2013265","journal-title":"Confin Neurol"},{"issue":"3","key":"8391_CR10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/archneurpsyc.1939.02270210129006","volume":"42","author":"RB Aird","year":"1939","unstructured":"Aird RB, Gurchot C (1939) Protective effect of cholesterol in experimental epilepsy. Arch Neurol Psychiatry 42(3):491\u2013506","journal-title":"Arch Neurol Psychiatry"},{"issue":"4","key":"8391_CR11","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/archneurpsyc.1939.02270220116007","volume":"42","author":"RB Aird","year":"1939","unstructured":"Aird RB (1939) Mode of action of brilliant vital red in epilepsy. Arch Neurol Psychiatry 42(4):700\u2013723","journal-title":"Arch Neurol Psychiatry"},{"key":"8391_CR12","first-page":"225","volume-title":"Chemistry and medicine","author":"I McQuarrie","year":"1940","unstructured":"McQuarrie I (1940) The physicochemical approach to the mechanisms of convulsive reactivity. In: Visscher MB (ed) Chemistry and medicine. University of Minnesota Press, Minneapolis, pp 225\u2013250"},{"issue":"12","key":"8391_CR13","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1001\/jama.1938.02790380010004","volume":"111","author":"H Merritt","year":"1938","unstructured":"Merritt H, Putnam TJ (1938) Sodium diphenyl hydantoinate in the treatment of convulsive disorders. J Am Med Assoc 111(12):1068\u20131073. doi: 10.1001\/jama.1938.02790380010004","journal-title":"J Am Med Assoc"},{"issue":"5","key":"8391_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/archneurpsyc.1938.02270050129007","volume":"39","author":"H Merritt","year":"1938","unstructured":"Merritt H, Putnam TJ (1938) A new series of anticonvulsant drugs tested by experiments on animals. Arch Neurol Psychiatry 39(5):1003\u20131015. doi: 10.1001\/archneurpsyc.1938.02270050129007","journal-title":"Arch Neurol Psychiatry"},{"issue":"6","key":"8391_CR15","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/archneurpsyc.1939.02270240091005","volume":"42","author":"H Merritt","year":"1939","unstructured":"Merritt H, Putnam TJ (1939) Sodium diphenyl hydantoinate in treatment of convulsive seizures: toxic symptoms and their prevention. Arch Neurol Psychiatry 42(6):1053\u20131058. doi: 10.1001\/archneurpsyc.1939.02270240091005","journal-title":"Arch Neurol Psychiatry"},{"issue":"21","key":"8391_CR16","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1001\/jama.1939.02800210084024","volume":"112","author":"TT Putnam","year":"1939","unstructured":"Putnam TT (1939) USe of sodium diphenyl hydantoinate as anticonvulsant. J Am Med Assoc 112(21):2190. doi: 10.1001\/jama.1939.02800210084024","journal-title":"J Am Med Assoc"},{"issue":"5","key":"8391_CR17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1176\/ajp.96.5.1023","volume":"96","author":"H Merritt","year":"1940","unstructured":"Merritt H, Putnam TJ (1940) Further experiences with the use of sodium diphenyl hydantoinate in the treatment of convulsive disorders. Am J Psychiatry 96(5):1023\u20131027. doi: 10.1176\/ajp.96.5.1023","journal-title":"Am J Psychiatry"},{"issue":"6018","key":"8391_CR18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/S0140-6736(00)84000-3","volume":"232","author":"WG Lennox","year":"1938","unstructured":"Lennox WG (1938) A new remedy for epilepsy? Lancet 232(6018):1544","journal-title":"Lancet"},{"issue":"13","key":"8391_CR19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/jama.1939.02800130028009","volume":"112","author":"O Kimball","year":"1939","unstructured":"Kimball O (1939) The treatment of epilepsy with sodium diphenyl hydantoinate. J Am Med Assoc 112(13):1244\u20131245. doi: 10.1001\/jama.1939.02800130028009","journal-title":"J Am Med Assoc"},{"issue":"3","key":"8391_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/bf01573141","volume":"14","author":"VI Bonafede","year":"1940","unstructured":"Bonafede VI, Nathan RE (1940) The treatment of epilepsy with sodium diphenyl hydantoinate. Psychiatr Q 14(3):603\u2013611. doi: 10.1007\/bf01573141","journal-title":"Psychiatr Q"},{"issue":"14","key":"8391_CR21","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1001\/jama.1940.02810140020005","volume":"114","author":"SI Frankel","year":"1940","unstructured":"Frankel SI (1940) Dilantin sodium in the treatment of epilepsy. J Am Med Assoc 114(14):1320\u20131321. doi: 10.1001\/jama.1940.02810140020005","journal-title":"J Am Med Assoc"},{"issue":"5","key":"8391_CR22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jama.1940.02810050016004","volume":"114","author":"JL Fetterman","year":"1940","unstructured":"Fetterman JL (1940) Dilantin sodium therapy in epilepsy: report of study in progress. J Am Med Assoc 114(5):396\u2013400. doi: 10.1001\/jama.1940.02810050016004","journal-title":"J Am Med Assoc"},{"issue":"14","key":"8391_CR23","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jama.1940.02810140034009","volume":"114","author":"LJ Robinson","year":"1940","unstructured":"Robinson LJ, Osgood R (1940) Comparative effects of phenobarbital and dilantin sodium: in the treatment of epilepsy. J Am Med Assoc 114(14):1334\u20131335. doi: 10.1001\/jama.1940.02810140034009","journal-title":"J Am Med Assoc"},{"issue":"364","key":"8391_CR24","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1192\/bjp.86.364.888","volume":"86","author":"D Blair","year":"1940","unstructured":"Blair D (1940) The modern treatment of epilepsy: a critical survey, with special reference to sodium diphenyl hydantoinate and a comparison of its effects with those of other anticonvulsants. Br J Psychiatry 86(364):888\u2013927. doi: 10.1192\/bjp.86.364.888","journal-title":"Br J Psychiatry"},{"issue":"364","key":"8391_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1192\/bjp.86.364.981","volume":"86","author":"BAM Williamson","year":"1940","unstructured":"Williamson BAM (1940) Severe toxic effects of sodium diphenyl hydantoinate in mentally defective epileptics. Br J Psychiatry 86(364):981\u2013987. doi: 10.1192\/bjp.86.364.981","journal-title":"Br J Psychiatry"},{"issue":"1","key":"8391_CR26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1590\/S0080-623420140000100021","volume":"48","author":"F Firmino","year":"2014","unstructured":"Firmino F, de Almeida AM, e Silva Rde J, Alves Gda S, Grandeiro Dda S, Penna LH (2014) Scientific production on the applicability of phenytoin in wound healing. Rev Esc Enferm USP 48(1):166\u2013173","journal-title":"Rev Esc Enferm USP"},{"issue":"2","key":"8391_CR27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3565(25)21797-9","volume":"228","author":"N Matsuki","year":"1984","unstructured":"Matsuki N, Quandt FN, Ten Eick RE, Yeh JZ (1984) Characterization of the block of sodium channels by phenytoin in mouse neuroblastoma cells. J Pharmacol Exp Ther 228(2):523\u2013530","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"8391_CR28","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-3565(25)21365-9","volume":"230","author":"RS Morello","year":"1984","unstructured":"Morello RS, Begenisich T, Yeh JZ (1984) Determination of the active form of phenytoin. J Pharmacol Exp Ther 230(1):156\u2013161","journal-title":"J Pharmacol Exp Ther"},{"issue":"31","key":"8391_CR29","first-page":"20","volume":"40","author":"JZ Yeh","year":"1981","unstructured":"Yeh JZ, Quandt FN, Kirsch GE (1981) Comparative studies of phenytoin action on ionic channels in excitable membranes. Fed Proc 40(31):20","journal-title":"Fed Proc"},{"key":"8391_CR30","first-page":"446","volume-title":"Goodman & Gilman\u2019s the pharmacological basis of therapeutics","author":"TW Rall","year":"1985","unstructured":"Rall TW, Schleiffer L (1985) Drugs effective in the treatment of the epilepsies. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds) Goodman & Gilman\u2019s the pharmacological basis of therapeutics, 7th edn. Macmillan, New York, pp 446\u2013472","edition":"7"},{"issue":"11","key":"8391_CR31","doi-asserted-by":"publisher","first-page":"5982","DOI":"10.1016\/j.bmc.2008.04.058","volume":"16","author":"J Handzlik","year":"2008","unstructured":"Handzlik J, Maciag D, Kubacka M, Mogilski S, Filipek B, Stadnicka K, Kiec-Kononowicz K (2008) Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin. Bioorg Med Chem 16(11):5982\u20135998. doi: 10.1016\/j.bmc.2008.04.058","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"8391_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1933719114549853","volume":"22","author":"A Fadiel","year":"2015","unstructured":"Fadiel A, Song J, Tivon D, Hamza A, Cardozo T, Naftolin F (2015) Phenytoin is an estrogen receptor alpha-selective modulator that interacts with helix 12. Reprod Sci 22(2):146\u2013155. doi: 10.1177\/1933719114549853","journal-title":"Reprod Sci"},{"issue":"10","key":"8391_CR33","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/nmo.12645","volume":"27","author":"R Patejdl","year":"2015","unstructured":"Patejdl R, Leroux AC, Noack T (2015) Phenytoin inhibits contractions of rat gastrointestinal and portal vein smooth muscle by inhibiting calcium entry. Neurogastroenterol Motil 27(10):1453\u20131465. doi: 10.1111\/nmo.12645","journal-title":"Neurogastroenterol Motil"},{"issue":"12","key":"8391_CR34","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1177\/0022034509350566","volume":"88","author":"AM Suzuki","year":"2009","unstructured":"Suzuki AM, Yoshimura A, Ozaki Y, Kaneko T, Hara Y (2009) Cyclosporin A and phenytoin modulate inflammatory responses. J Dent Res 88(12):1131\u20131136. doi: 10.1177\/0022034509350566","journal-title":"J Dent Res"},{"issue":"3","key":"8391_CR35","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.bmc.2010.11.051","volume":"19","author":"J Handzlik","year":"2011","unstructured":"Handzlik J, Szymanska E, Nedza K, Kubacka M, Siwek A, Mogilski S, Filipek B, Kiec-Kononowicz K (2011) Pharmacophore models based studies on the affinity and selectivity toward 5-HT1A with reference to alpha 1-adrenergic receptors among arylpiperazine derivatives of phenytoin. Bioorg Med Chem 19(3):1349\u20131360. doi: 10.1016\/j.bmc.2010.11.051","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"8391_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/syn.20103","volume":"55","author":"EJ Cobos","year":"2005","unstructured":"Cobos EJ, Baeyens JM, Del Pozo E (2005) Phenytoin differentially modulates the affinity of agonist and antagonist ligands for sigma 1 receptors of guinea pig brain. Synapse 55(3):192\u2013195. doi: 10.1002\/syn.20103","journal-title":"Synapse"},{"issue":"7","key":"8391_CR37","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0306-3623(96)00062-6","volume":"27","author":"G Tunnicliff","year":"1996","unstructured":"Tunnicliff G (1996) Basis of the antiseizure action of phenytoin. Gen Pharmacol 27(7):1091\u20131097","journal-title":"Gen Pharmacol"},{"issue":"1","key":"8391_CR38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1007688817873","volume":"26","author":"IE Holopainen","year":"2001","unstructured":"Holopainen IE, Kivela R, Korpi ER (2001) Do antiepileptics phenytoin, carbamazepine, and loreclezole show GABA(A) receptor subtype selectivity in rat brain sections? Neurochem Res 26(1):89\u201394","journal-title":"Neurochem Res"},{"issue":"3","key":"8391_CR39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1254\/jjp.46.261","volume":"46","author":"PT Wong","year":"1988","unstructured":"Wong PT, Teo WL (1988) Properties of phenytoin binding sites in the rat brain: regional distribution and postnatal development. Jpn J Pharmacol 46(3):261\u2013266","journal-title":"Jpn J Pharmacol"},{"issue":"Pt 9","key":"8391_CR40","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/brain\/aws225","volume":"135","author":"N Eijkelkamp","year":"2012","unstructured":"Eijkelkamp N, Linley JE, Baker MD, Minett MS, Cregg R, Werdehausen R, Rugiero F, Wood JN (2012) Neurological perspectives on voltage-gated sodium channels. Brain 135(Pt 9):2585\u20132612","journal-title":"Brain"},{"issue":"4","key":"8391_CR41","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0026-895X(24)13073-8","volume":"54","author":"CC Kuo","year":"1998","unstructured":"Kuo CC (1998) A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol 54(4):712\u2013721","journal-title":"Mol Pharmacol"},{"issue":"3","key":"8391_CR42","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.eplepsyres.2005.03.003","volume":"64","author":"PT Lucas","year":"2005","unstructured":"Lucas PT, Meadows LS, Nicholls J, Ragsdale DS (2005) An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin. Epilepsy Res 64(3):77\u201384. doi: 10.1016\/j.eplepsyres.2005.03.003","journal-title":"Epilepsy Res"},{"issue":"1","key":"8391_CR43","doi-asserted-by":"publisher","first-page":"e55329","DOI":"10.1371\/journal.pone.0055329","volume":"8","author":"E Colombo","year":"2013","unstructured":"Colombo E, Franceschetti S, Avanzini G, Mantegazza M (2013) Phenytoin inhibits the persistent sodium current in neocortical neurons by modifying its inactivation properties. PLoS One 8(1):e55329. doi: 10.1371\/journal.pone.0055329","journal-title":"PLoS One"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-017-8391-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-017-8391-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:19:32Z","timestamp":1749896372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-017-8391-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,12]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["8391"],"URL":"https:\/\/doi.org\/10.1007\/s00415-017-8391-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,12]]}}}